ClinicalTrials.gg
CompletedNCT00508261Updated Jan 24, 2019Results posted

Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine

A Phase 3 interventional study of Meningococcal vaccine GSK134612 and Infanrix™ hexa in Infections, Meningococcal, sponsored by GlaxoSmithKline. Completed at 89 sites in 3 countries. Open to participants aged 12 Months to 23 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-24.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
793
Allocation
Randomized
Ages
12 Months to 23 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 71 studies in Meningococcal Infections by GlaxoSmithKline — none open to participants now, 1 under way, none of them phase 3. Meningococcal Infections · GlaxoSmithKline.

Enrollment
24th of 67
793 · median 613
Started
2007
with 11 others
Phase 3
34 of 71
none open now
Registered
26th of 71
by date

Among the 71 studies in Meningococcal Infections by GlaxoSmithKline, this one is the 24th largest by enrollment of the 67 interventional ones that give a count, is one of 12 that started in 2007, is one of 34 in phase 3, and was the 26th registered.

Meningococcal Infections

243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.

Browse Meningococcal Infections studies →

Open to participants now

None of the 71 studies in Meningococcal Infections by GlaxoSmithKline is open now. The open studies under Meningococcal Infections, anywhere →

Who these studies take

Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 12 Months to 23 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 71 studies in Meningococcal Infections by GlaxoSmithKline as a file.
02

Study summary

The purpose of this study is to demonstrate, in 12-23 months old subjects, the non-inferiority of meningococcal vaccine GSK134612 co-administered with Infanrix hexa™, compared to each vaccine administered individually and to licensed meningococcal vaccine Meningitec™.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Read the detailed description

Multicentre study with 4 parallel groups. One group will receive GSK134612 co-administered with Infanrix hexa™, two groups will receive sequential administration of GSK134612 and Infanrix hexa™ and the final group will receive Meningitec™.

For subjects in Groups B and C, three blood samples will be taken: prior to first vaccination and 1 month after each vaccination.

For subjects in Groups A and D, two blood samples will be taken: prior to and 1 month after vaccination.

03

Conditions studied

  • Infections, Meningococcal

Keywords

  • Meningococcal vaccine
  • Immunogenicity
  • Routine infancy vaccination
  • Safety
04

Who can participate

Ages eligible
12 Months to 23 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.
  • A male or female between, and including, 12 and 23 months of age at the time of the first vaccination.
  • Written obtained from the parent or guardian of the subject.
  • Free of obvious health problems as established by medical history and clinical examination before entering into the study.
  • Documented three-dose primary vaccination with DTPa, , inactivated polio and Haemophilus influenzae type b conjugate vaccines, completed at least 180 days before administration of the first study vaccination.

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Chronic administration (defined as more than 14 days) of or other immune-modifying drugs within six months prior to the first vaccine dose.
  • Planned administration/ administration of any vaccine not foreseen by the study protocol, including measles, mumps, rubella, varicella and pneumococcal vaccines, within 30 days before the first dose of vaccine(s) and 30 days after the last dose of vaccine(s).
  • Previous vaccination with meningococcal polysaccharide vaccine of serogroup A, C, W and/or Y.
  • Previous vaccination with meningococcal polysaccharide conjugate vaccine of serogroup A, C, W and/or Y.
  • Previous booster vaccination against diphtheria, tetanus, pertussis, , poliomyelitis or Haemophilus influenzae type b.
  • History of meningococcal disease.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital or secondary), including (HIV) infection, based on medical history and physical examination.
  • History of reactions or allergic disease likely to be exacerbated by any component of the vaccine(s).
  • Major congenital defects or serious chronic illness.
  • Acute disease at the time of enrolment.
  • Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.

Additional criteria for subjects receiving Infanrix hexa™

  • reaction due to previous vaccination with Infanrix hexa™.
  • Encephalopathy defined as an acute, severe central nervous system disorder occurring within 7 days following vaccination and generally consisting of major alterations in consciousness, unresponsiveness, generalised or focal seizures that persist more than a few hours, with failure to recover within 24 hours.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
793 participants (actual)

Study arms

  • Experimental
    Group A

    Meningococcal vaccine GSK134612 co-administered with Infanrix hexa™

    Biological: Meningococcal vaccine GSK134612 · Biological: Infanrix™ hexa

  • Experimental
    Group B

    Meningococcal vaccine GSK134612 followed one month later by Infanrix hexa™

    Biological: Meningococcal vaccine GSK134612 · Biological: Infanrix™ hexa

  • Active comparator
    Group C

    Infanrix hexa™ followed one month later by Meningococcal vaccine GSK134612

    Biological: Meningococcal vaccine GSK134612 · Biological: Infanrix™ hexa

  • Active comparator
    Group D

    Meningitec™ vaccination

    Biological: Meningitec™

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers ≥ the Cut-off.

    The cut-off for the assay was greater than or equal to (≥) 1:8. The analysis was based only on subjects receiving Nimenrix vaccination at Day 0.

    Time frame: 1 month after vaccination with Nimenrix vaccine (Month 1)

  2. Anti-PT, Anti-FHA and Anti-PRN Concentrations

    The analysis was based only on subjects receiving Infanrix-hexa vaccination. The results were calculated as geometric mean expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).

    Time frame: 1 month after the first vaccination (Month 1)

  3. Number of Subjects With Anti-HBs Concentrations ≥ the Cut-off

    The cut-off for the assay was greater than or equal to (≥) 10 milli-interantional units per milliliter (mIU/mL).

    Time frame: 1 month after vaccination with Nimenrix vaccine (Month 1)

  4. Number of Subjects With Anti-PRP Concentrations ≥ the Cut-off

    The cut-off for the assay was ≥ 1μg/mL.

    Time frame: 1 month after vaccination with Nimenrix vaccine (Month 1)

Secondary outcomes

  1. Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers ≥ the Cut-off Values

    The cut-off values for the assay were ≥ 1:8 and ≥ 1:128

    Time frame: At month 0, month 1 and month 2

  2. rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers

    The results were tabulated as geometric mean expressed in titers.

    Time frame: At month 0, month 1 and month 2

  3. Number of Subjects With Anti-polysaccharide A (Anti-PSA), Anti-PSC, Anti-PSW, and Anti-PSY ≥ the Cut-off

    The cut-off for the assay were ≥ 0.3 microgram per milliliter (μg/mL) and ≥ 2.0 μg/mL, respectively.

    Time frame: At month 0, month 1 and month 2

  4. Anti-polysaccharide A (Anti-PSA), Anti-PSC, Anti-PSW, and Anti-PSY Antibody Concentrations

    The results for the assay were tabulated as geometric mean expressed in microgram per milliliter (μg/mL).

    Time frame: At month 0, month 1 and month 2

  5. Number of Seroprotected Subjects for Anti-tetanus Toxoid (Anti-TT)

    The cut-off for the assay was ≥ 0.1

    Time frame: At month 0, month 1 and month 2

  6. Anti-tetanus Toxoid (Anti-TT) Antibody Concentrations

    The results for the assay were tabulated as geometric mean expressed in internationl units per milliliter (IU/mL).

    Time frame: At month 0, month 1 and month 2

  7. Number of Subjects Seroprotected for Anti-diphtheria (Anti-D) ≥ the Cut-off

    The cut-off for the assay was ≥ 0.1

    Time frame: At month 0, month 1 and month 2

  8. Anti-diphtheria (Anti-D) Antibody Concentrations

    The results for the assay were tabulated as geometric mean expressed in internationl units per milliliter (IU/mL).

    Time frame: At month 0, month 1 and month 2

  9. Number of Subjects Seroprotected for Anti-polio Type 1, 2 & 3 ≥ the Cut-off

    The cut-off for the assay was ≥ 1:8.

    Time frame: At month 0, month 1 and month 2

  10. Anti-polio Type 1, 2 & 3 Titers

    The results for the assay were tabulated as geometric mean expressed in titers.

    Time frame: At month 0, 1 and 2

  11. Numbers of Seroprotected Subjects for Anti-PRP ≥ the Cut-off

    The cut-off for the assay was ≥ 1.0

    Time frame: At month 0, month 1 and month 2

  12. Anti-PRP Antibody Concentrations

    The results for the assay were tabulated as geometric mean expressed in microgram per milliliter (μg/mL).

    Time frame: At month 0, month 1 and month 2

  13. Number of Seroprotected Subjects for Anti-HBs ≥ the Cut-offs

    The cut-offs for the assay were ≥ 10 mIU/mL and ≥ 100 mIU/mL respectively .

    Time frame: At month 0, month 1 and month 2

  14. Anti-HBs Antibody Concentrations

    The results for the assay were tabulated as geometric mean expressed in milli-international units per milliliter (mIU/mL).

    Time frame: At month 0, month 1 and month 2

  15. Number of Subjects With a Vaccine Response to PT, FHA and PRN Antigens

    Vaccine response to these antigens is defined as appearance of antibodies in subjects who were seronegative (antibody concentration \< 5 EL.U/mL) at pre-vaccination or as at least a 2-fold increase in post-over pre-vaccination antibody concentrations in subjects seropositive at pre-vaccination. The analysis was based only on subjects receiving experimental vaccination.

    Time frame: 1 month after vaccination (Month 1)

  16. Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations

    The results were tabulated as geometric mean expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).

    Time frame: At month 0, month 1 and month 2

  17. Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms Post-meningococcal Vaccination

    Solicited local symptoms assessed were pain, redness and swelling. Any was defined as occurrence of any local symptom irrespective of intensity grade. Grade 3 Pain was defined as crying when limb was moved/ spontaneously painful.

    Time frame: During the 4-day (Days 0-3) follow-up period after Nimenrix or Meningitec vaccination

  18. Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms Post-combined Diphtheria Vaccination

    The analysis was based only on subjects receiving combined-diphtheria vaccination.

    Time frame: During the 4-day (Days 0-3) follow-up period after Infanrix-hexa vaccination

  19. Number of Subjects Reporting Any Solicited General Symptoms Following Each Dose

    Solicited general symptoms assessed were drowsiness, fever, irritability and loss of appetite. Any was defined as occurrence of any general symptom irrespective of intensity grade and relationship. Subjects in the Nimenrix + Infanrix-hexa Group did not receive a second dose of vaccination.

    Time frame: During the 4-day (Days 0-3) post-vaccination dose 1 (D1) and second dose (D2)

  20. Number of Subjects Reporting Any Rash

    Any was defined as occurrence of at least one symptom experienced.

    Time frame: Day 0 - Month 7

  21. Number of Subjects Reporting Any New Onset of Chronic Illnesses (NOCIs)

    Any was defined as occurrence of at least one symptom experienced.

    Time frame: Day 0 - Month 7

  22. Number of Subjects Reporting Any Conditions Prompting Emergency Room Visits (ER)

    Any was defined as occurrence of at least one symptom experienced.

    Time frame: Day 0 - Month 7

  23. Number of Subjects Reporting Any Unsolicited Adverse Events (AEs) After the First Dose

    An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. "Any" was defined as an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.

    Time frame: Occurring within Day 0-30 following vaccination

  24. Number of Subjects Reporting Any Unsolicited Adverse Events (AEs) After the Second Dose

    An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. "Any" was defined as an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination. The analysis was based only on subjects receiving a second dose of vaccination.

    Time frame: Occurring within Day 0-30 following vaccination

  25. Number of Subjects Reporting Any Serious Adverse Events (SAEs)

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/ incapacity.

    Time frame: From dose 1 (Month 0) up to study end (Month 7)

07

Results

Posted Jan 24, 2019

Participant flow

Participant flow — Overall Study
MilestoneNimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa GroupMeningitec Group
Started222220224127
Completed219212218126
Not completed3861
Withdrew: Other0110
Withdrew: Serious adverse event0100
Withdrew: Withdrawal by subject3440
Withdrew: Migrated/ moved from study area0100
Withdrew: Lost to follow-up0111

Outcome measures

PrimaryNumber of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers ≥ the Cut-off.

The cut-off for the assay was greater than or equal to (≥) 1:8. The analysis was based only on subjects receiving Nimenrix vaccination at Day 0.

Time frame:
1 month after vaccination with Nimenrix vaccine (Month 1)
Reported as:
Count of participants · Participants
Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers ≥ the Cut-off.
ParticipantsNimenrix + Infanrix-hexa GroupNimenrix Group
rSBA-MenA, M1193180
rSBA-MenC, M1191178
rSBA-MenW-135, M1193183
rSBA-MenY, M1192180
Statistical analysis
  • Nimenrix + Infanrix-hexa Group vs Nimenrix Group · Difference in percentages: 1.64 · 95% CI -0.33 to 4.71
  • Nimenrix + Infanrix-hexa Group vs Nimenrix Group · Difference in percentages: 2.73 · 95% CI 0.73 to 6.24
  • Nimenrix + Infanrix-hexa Group vs Nimenrix Group · Difference in percentages: 1.61 · 95% CI -0.36 to 4.64
  • Nimenrix + Infanrix-hexa Group vs Nimenrix Group · Difference in percentages: 2.7 · 95% CI 0.71 to 6.18
PrimaryAnti-PT, Anti-FHA and Anti-PRN Concentrations

The analysis was based only on subjects receiving Infanrix-hexa vaccination. The results were calculated as geometric mean expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).

Time frame:
1 month after the first vaccination (Month 1)
Reported as:
Geometric mean · EL.U/mL
Anti-PT, Anti-FHA and Anti-PRN Concentrations
EL.U/mLNimenrix + Infanrix-hexa GroupInfanrix-Hexa Group
Anti-PT, M186 (77 to 95)85 (75 to 96)
Anti-FHA, M1542 (492 to 597)544 (485 to 611)
Anti-PRN, M1470 (411 to 537)450 (387 to 522)
Statistical analysis
  • Nimenrix + Infanrix-hexa Group vs Infanrix-Hexa Group · Adjusted gmc ratios: 0.97 · 95% CI 0.83 to 1.12
  • Nimenrix + Infanrix-hexa Group vs Infanrix-Hexa Group · Adjusted gmc ratios: 0.98 · 95% CI 0.85 to 1.13
  • Nimenrix + Infanrix-hexa Group vs Infanrix-Hexa Group · Adjusted gmc ratios: 0.92 · 95% CI 0.78 to 1.1
PrimaryNumber of Subjects With Anti-HBs Concentrations ≥ the Cut-off

The cut-off for the assay was greater than or equal to (≥) 10 milli-interantional units per milliliter (mIU/mL).

Time frame:
1 month after vaccination with Nimenrix vaccine (Month 1)
Reported as:
Count of participants · Participants
Number of Subjects With Anti-HBs Concentrations ≥ the Cut-off
ParticipantsNimenrix + Infanrix-hexa GroupInfanrix-Hexa Group
Number of Subjects With Anti-HBs Concentrations ≥ the Cut-off180166
Statistical analysis
  • Nimenrix + Infanrix-hexa Group vs Infanrix-Hexa Group · Difference in percentages: 1.22 · 95% CI -1.47 to 4.6
PrimaryNumber of Subjects With Anti-PRP Concentrations ≥ the Cut-off

The cut-off for the assay was ≥ 1μg/mL.

Time frame:
1 month after vaccination with Nimenrix vaccine (Month 1)
Reported as:
Count of participants · Participants
Number of Subjects With Anti-PRP Concentrations ≥ the Cut-off
ParticipantsNimenrix + Infanrix-hexa GroupInfanrix-Hexa Group
Number of Subjects With Anti-PRP Concentrations ≥ the Cut-off183170
Statistical analysis
  • Nimenrix + Infanrix-hexa Group vs Infanrix-Hexa Group · Difference in percentages: 1.19 · 95% CI -1.45 to 4.5
SecondaryNumber of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers ≥ the Cut-off Values

The cut-off values for the assay were ≥ 1:8 and ≥ 1:128

Time frame:
At month 0, month 1 and month 2
Reported as:
Count of participants · Participants
Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers ≥ the Cut-off Values
ParticipantsNimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa GroupMeningitec Group
rSBA-MenA [M 0], ≥1:830323418
rSBA-MenA [M 1], ≥1:81931807143
rSBA-MenA [M 2], ≥1:8—90178—
rSBA-MenA [M 0], ≥1:12818212411
rSBA-MenA [M 1], ≥1:1281931795730
rSBA-MenA [M 2], ≥1:128—90178—
rSBA-MenC [M 0], ≥1:820251311
rSBA-MenC [M 1], ≥1:819117834112
rSBA-MenC [M 2], ≥1:8—91178—
rSBA-MenC [M 0], ≥1:1285853
rSBA-MenC [M 1], ≥1:12818917214102
rSBA-MenC [M 2], ≥1:128—85157—
rSBA-MenW-135 [M 0], ≥1:843424622
rSBA-MenW-135 [M 1], ≥1:81931838641
rSBA-MenW-135 [M 2], ≥1:8—91179—
rSBA-MenW-135 [M 0], ≥1:12817112310
rSBA-MenW-135 [M 1] ≥1:1281931804923
rSBA-MenW-135 [M 2], ≥1:128—90178—
rSBA-MenY [M 0], ≥1:857535330
rSBA-MenY [M 1], ≥1:819218010371
rSBA-MenY [M 2], ≥1:8—91178—
rSBA-MenY [M 0], ≥1:12838373420
rSBA-MenY [M 1], ≥1:1281921787938
rSBA-MenY [M 2], ≥1:128—91178—
SecondaryrSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers

The results were tabulated as geometric mean expressed in titers.

Time frame:
At month 0, month 1 and month 2
Reported as:
Geometric mean · Titers
rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers
TitersNimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa GroupMeningitec Group
rSBA-MenA [M 0]15 (10 to 22.4)19 (12.2 to 29.5)24 (15 to 38.4)15.9 (9.2 to 27.5)
rSBA-MenA [M 1]3152.9 (2752.5 to 3611.4)3169.9 (2577.2 to 3898.8)24.2 (17.4 to 33.7)21.5 (14.5 to 32.1)
rSBA-MenA [M 2]—2881.9 (2292 to 3623.6)1938.3 (1699.1 to 2211.2)—
rSBA-MenC [M 0]7.4 (5.7 to 9.6)9.1 (6.7 to 12.2)6.1 (4.9 to 7.7)7.6 (5.2 to 11.2)
rSBA-MenC [M 1]879.7 (763.1 to 1014)828.7 (672.4 to 1021.4)7.5 (6.1 to 9.3)691.4 (520.8 to 917.9)
rSBA-MenC [M 2]—519.6 (391.7 to 689.2)386 (333.9 to 446.2)—
rSBA-MenW-135 [M 0]19 (13.1 to 27.6)19.2 (13.3 to 27.7)24.8 (16.7 to 36.8)15.6 (9.8 to 25)
rSBA-MenW-135 [M 1]4147 (3670.1 to 4685.8)4022.3 (3269.2 to 4948.8)25.2 (18.6 to 34.2)14.2 (10.2 to 19.7)
rSBA-MenW-135 [M 2]—3630.1 (2899.1 to 4545.4)2466.4 (2175.4 to 2796.4)—
rSBA-MenY [M 0]36.8 (24.7 to 54.8)45.4 (29.1 to 71)41.2 (26.7 to 63.4)32 (18.3 to 55.9)
rSBA-MenY [M 1]3461.8 (2990.1 to 4007.9)3167.7 (2521.9 to 3978.9)45.9 (33 to 63.9)47.2 (32.1 to 69.3)
rSBA-MenY [M 2]—3010.4 (2325.3 to 3897.3)2446.9 (2088.5 to 2866.8)—
SecondaryNumber of Subjects With Anti-polysaccharide A (Anti-PSA), Anti-PSC, Anti-PSW, and Anti-PSY ≥ the Cut-off

The cut-off for the assay were ≥ 0.3 microgram per milliliter (μg/mL) and ≥ 2.0 μg/mL, respectively.

Time frame:
At month 0, month 1 and month 2
Reported as:
Count of participants · Participants
Number of Subjects With Anti-polysaccharide A (Anti-PSA), Anti-PSC, Anti-PSW, and Anti-PSY ≥ the Cut-off
ParticipantsNimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa GroupMeningitec Group
Anti-PSA [Month 0], ≥0.34111
Anti-PSA [Month 1], ≥0.3464511
Anti-PSA [Month 2], ≥0.3—4442—
Anti-PSA [Month 0], ≥2.00000
Anti-PSA [Month 1], ≥2.0464410
Anti-PSA [Month 2], ≥2.0043400
Anti-PSC [Month 0], ≥0.31120
Anti-PSC [Month 1], ≥0.35141228
Anti-PSC [Month 2], ≥0.3—4147—
Anti-PSC [Month 0], ≥2.01000
Anti-PSC [Month 1], ≥2.05041026
Anti-PSC [Month 2], ≥2.0—4143—
Anti-PSW-135 [Month 0], ≥0.31120
Anti-PSW-135 [Month 1], ≥0.3444320
Anti-PSW-135 [Month 2], ≥0.3043410
Anti-PSW-135 [Month 0], ≥2.00010
Anti-PSW-135 [Month 1], ≥2.0403920
Anti-PSW-135 [Month 2], ≥2.0—3629—
Anti-PSY [Month 0], ≥0.31100
Anti-PSY [Month 1], ≥0.3454310
Anti-PSY [Month 2], ≥0.3—4441—
Anti-PSY [Month 0], ≥2.00000
Anti-PSY [Month 1], ≥2.0404210
Anti-PSY [Month 2], ≥2.0—4034—
SecondaryAnti-polysaccharide A (Anti-PSA), Anti-PSC, Anti-PSW, and Anti-PSY Antibody Concentrations

The results for the assay were tabulated as geometric mean expressed in microgram per milliliter (μg/mL).

Time frame:
At month 0, month 1 and month 2
Reported as:
Geometric mean · μg/mL
Anti-polysaccharide A (Anti-PSA), Anti-PSC, Anti-PSW, and Anti-PSY Antibody Concentrations
μg/mLNimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa GroupMeningitec Group
Anti-PSA [M 0]0.17 (0.15 to 0.19)0.15 (0.15 to 0.16)0.16 (0.14 to 0.18)0.16 (0.14 to 0.18)
Anti-PSA [M 1]31.01 (23.73 to 40.52)33.15 (21.89 to 50.18)0.17 (0.13 to 0.22)0.16 (0.14 to 0.18)
Anti-PSA [M 2]—16.93 (12.39 to 23.13)12.28 (9.38 to 16.06)—
Anti-PSC [M 0]0.16 (0.14 to 0.2)0.16 (0.14 to 0.17)0.16 (0.15 to 0.17)0.15 (0.15 to 0.15)
Anti-PSC [M 1]13.74 (10.68 to 17.67)23.52 (18.91 to 29.25)0.16 (0.15 to 0.17)7.99 (5.57 to 11.46)
Anti-PSC [M 2]—9.73 (7.82 to 12.12)5.84 (4.66 to 7.32)—
Anti-PSW-135 [M 0]0.16 (0.14 to 0.17)0.15 (0.15 to 0.16)0.17 (0.14 to 0.22)0.15 (0.15 to 0.15)
Anti-PSW-135 [M 1]6.43 (4.92 to 8.4)4.15 (2.82 to 6.11)0.18 (0.14 to 0.22)0.15 (0.15 to 0.15)
Anti-PSW-135 [M 2]—3.99 (2.91 to 5.48)3.4 (2.52 to 4.59)—
Anti-PSY [M 0]0.15 (0.15 to 0.16)0.15 (0.15 to 0.16)0.15 (0.15 to 0.15)0.15 (0.15 to 0.15)
Anti-PSY [M 1]6.52 (4.91 to 8.65)9.42 (6.49 to 13.66)0.17 (0.13 to 0.21)0.15 (0.15 to 0.15)
Anti-PSY [M 2]—7.86 (6.04 to 10.23)4.76 (3.73 to 6.09)—
SecondaryNumber of Seroprotected Subjects for Anti-tetanus Toxoid (Anti-TT)

The cut-off for the assay was ≥ 0.1

Time frame:
At month 0, month 1 and month 2
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects for Anti-tetanus Toxoid (Anti-TT)
ParticipantsNimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa GroupMeningitec Group
anti-TT [M 0], ≥0.117716115599
anti-TT [M 1], ≥0.118417717399
anti-TT [M 2], ≥0.1—177176—
SecondaryAnti-tetanus Toxoid (Anti-TT) Antibody Concentrations

The results for the assay were tabulated as geometric mean expressed in internationl units per milliliter (IU/mL).

Time frame:
At month 0, month 1 and month 2
Reported as:
Geometric mean · IU/mL
Anti-tetanus Toxoid (Anti-TT) Antibody Concentrations
IU/mLNimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa GroupMeningitec Group
anti-TT [M 0]0.481 (0.417 to 0.554)0.39 (0.332 to 0.457)0.416 (0.354 to 0.489)0.393 (0.325 to 0.475)
anti-TT [M 1]10.47 (9.131 to 12.007)7.941 (6.517 to 9.677)6.189 (5.404 to 7.089)0.374 (0.306 to 0.457)
anti-TT [M 2]—13.966 (12.199 to 15.987)8.236 (7.348 to 9.231)—
SecondaryNumber of Subjects Seroprotected for Anti-diphtheria (Anti-D) ≥ the Cut-off

The cut-off for the assay was ≥ 0.1

Time frame:
At month 0, month 1 and month 2
Reported as:
Count of participants · Participants
Number of Subjects Seroprotected for Anti-diphtheria (Anti-D) ≥ the Cut-off
ParticipantsNimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa GroupMeningitec Group
anti-D [M 0], ≥0.116915715494
anti-D [M 1], ≥0.1184156173109
anti-D [M 2], ≥0.1—176176—
SecondaryAnti-diphtheria (Anti-D) Antibody Concentrations

The results for the assay were tabulated as geometric mean expressed in internationl units per milliliter (IU/mL).

Time frame:
At month 0, month 1 and month 2
Reported as:
Geometric mean · IU/mL
Anti-diphtheria (Anti-D) Antibody Concentrations
IU/mLNimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa GroupMeningitec Group
anti-D [M 0]0.477 (0.407 to 0.559)0.476 (0.397 to 0.57)0.437 (0.367 to 0.521)0.452 (0.355 to 0.574)
anti-D [M 1]7.636 (6.889 to 8.465)0.404 (0.335 to 0.487)7.292 (6.362 to 8.358)5.201 (4.243 to 6.376)
anti-D [M 2]—8.561 (7.553 to 9.703)5.21 (4.623 to 5.872)—
SecondaryNumber of Subjects Seroprotected for Anti-polio Type 1, 2 & 3 ≥ the Cut-off

The cut-off for the assay was ≥ 1:8.

Time frame:
At month 0, month 1 and month 2
Reported as:
Count of participants · Participants
Number of Subjects Seroprotected for Anti-polio Type 1, 2 & 3 ≥ the Cut-off
ParticipantsNimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa GroupMeningitec Group
anti-p1 [M 0]15814314290
anti-p1 [M 1]16614916389
anti-p1 [M 2]—159161—
anti-p2 [M 0]15314114580
anti-p2 [M 1]16614716180
anti-p2 [M 2]—159161—
anti-p3 [M 0]15514814388
anti-p3 [M 1]16715016087
anti-p3 [M 2]—159159—
SecondaryAnti-polio Type 1, 2 & 3 Titers

The results for the assay were tabulated as geometric mean expressed in titers.

Time frame:
At month 0, 1 and 2
Reported as:
Geometric mean · Titers
Anti-polio Type 1, 2 & 3 Titers
TitersNimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa GroupMeningitec Group
anti-p1 [M 0]84.2 (67.2 to 105.4)72.5 (55.6 to 94.5)83.6 (65.5 to 106.6)71.7 (51.7 to 99.6)
anti-p1 [M 1]984.4 (830.4 to 1167)74.2 (56.7 to 97.3)1308.5 (1073.2 to 1595.5)66.3 (46.6 to 94.4)
anti-p1 [M 2]—1288.2 (1052.5 to 1576.6)1108.4 (913.5 to 1344.8)—
anti-p2 [M 0]76.8 (60.8 to 97)66.3 (50.9 to 86.5)65.6 (51.2 to 84.2)49.3 (34.9 to 69.6)
anti-p2 [M 1]1372 (1153.5 to 1631.9)70.3 (53.4 to 92.6)1540.4 (1253.2 to 1893.2)49.8 (34.5 to 71.9)
anti-p2 [M 2]—1650.5 (1358.5 to 2005.3)1174.5 (961.4 to 1434.8)—
anti-p3 [M 0]104.4 (81.1 to 134.4)99.8 (77.5 to 128.5)113.2 (86.9 to 147.5)102.9 (72.8 to 145.4)
anti-p3 [M 1]2295.6 (1952.1 to 2699.4)96.6 (74.2 to 125.8)2034.3 (1594.9 to 2594.8)85.3 (58.7 to 124.1)
anti-p3 [M 2]—2478 (2049.2 to 2996.4)1655.1 (1308.9 to 2092.9)—
SecondaryNumbers of Seroprotected Subjects for Anti-PRP ≥ the Cut-off

The cut-off for the assay was ≥ 1.0

Time frame:
At month 0, month 1 and month 2
Reported as:
Count of participants · Participants
Numbers of Seroprotected Subjects for Anti-PRP ≥ the Cut-off
ParticipantsNimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa GroupMeningitec Group
anti-PRP [M 0] ≥1.073646534
anti-PRP [M 1] ≥1.01837017034
anti-PRP [M 2] ≥1.0—172170—
SecondaryAnti-PRP Antibody Concentrations

The results for the assay were tabulated as geometric mean expressed in microgram per milliliter (μg/mL).

Time frame:
At month 0, month 1 and month 2
Reported as:
Geometric mean · μg/mL
Anti-PRP Antibody Concentrations
μg/mLNimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa GroupMeningitec Group
anti-PRP [M 0]0.806 (0.658 to 0.987)0.665 (0.528 to 0.839)0.766 (0.596 to 0.986)0.585 (0.449 to 0.762)
anti-PRP [M 1]25.556 (21.358 to 30.579)0.711 (0.56 to 0.904)31.165 (25.142 to 38.631)0.55 (0.42 to 0.72)
anti-PRP [M 2]—12.239 (10.392 to 14.414)21.023 (17.036 to 25.942)—
SecondaryNumber of Seroprotected Subjects for Anti-HBs ≥ the Cut-offs

The cut-offs for the assay were ≥ 10 mIU/mL and ≥ 100 mIU/mL respectively .

Time frame:
At month 0, month 1 and month 2
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects for Anti-HBs ≥ the Cut-offs
ParticipantsNimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa GroupMeningitec Group
anti-HBS [M 0] ≥1017315815595
anti-HBS [M 1] ≥10180160166100
anti-HBS [M 2] ≥10—172167—
anti-HBS [M 0] ≥10092807546
anti-HBS [M 1] ≥1001698515546
anti-HBS [M 2] ≥100—168158—
SecondaryAnti-HBs Antibody Concentrations

The results for the assay were tabulated as geometric mean expressed in milli-international units per milliliter (mIU/mL).

Time frame:
At month 0, month 1 and month 2
Reported as:
Geometric mean · mIU/mL
Anti-HBs Antibody Concentrations
mIU/mLNimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa GroupMeningitec Group
anti-HBS [M 0]111.6 (90.9 to 136.9)92.8 (75.3 to 114.4)101.2 (81.5 to 125.7)85.6 (65.7 to 111.5)
anti-HBS [M 1]2048.4 (1589.3 to 2640)95 (74.8 to 120.6)1711.6 (1292.7 to 2266.3)101.6 (75.5 to 136.7)
anti-HBS [M 2]—2392.3 (1841.7 to 3107.4)1241 (976.2 to 1577.7)—
SecondaryNumber of Subjects With a Vaccine Response to PT, FHA and PRN Antigens

Vaccine response to these antigens is defined as appearance of antibodies in subjects who were seronegative (antibody concentration \< 5 EL.U/mL) at pre-vaccination or as at least a 2-fold increase in post-over pre-vaccination antibody concentrations in subjects seropositive at pre-vaccination. The analysis was based only on subjects receiving experimental vaccination.

Time frame:
1 month after vaccination (Month 1)
Reported as:
Count of participants · Participants
Number of Subjects With a Vaccine Response to PT, FHA and PRN Antigens
ParticipantsNimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa Group
Anti-PT180169163
Anti-FHA184159158
Anti-PRN186173172
SecondaryAnti-PT, Anti-FHA and Anti-PRN Antibody Concentrations

The results were tabulated as geometric mean expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).

Time frame:
At month 0, month 1 and month 2
Reported as:
Geometric mean · EL.U/mL
Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations
EL.U/mLNimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa GroupMeningitec Group
Anti-PT [M 0]11 (10 to 12)10 (8 to 11)10 (9 to 12)11 (9 to 13)
Anti-PT [M 1]86 (77 to 95)8 (7 to 9)85 (75 to 96)9 (7 to 10)
Anti-PT [M 2]—91 (80 to 102)63 (55 to 71)—
Anti-FHA [M 0]51 (44 to 59)55 (46 to 66)49 (41 to 57)55 (44 to 68)
Anti-FHA [M 1]542 (492 to 597)48 (40 to 58)544 (485 to 611)55 (42 to 71)
Anti-FHA [M 2]—664 (664 to 750)413 (366 to 465)—
Anti-PRN [M 0]26 (23 to 31)26 (22 to 31)21 (17 to 24)23 (18 to 28)
Anti-PRN [M 1]470 (411 to 537)23 (19 to 27)450 (387 to 522)21 (16 to 26)
Anti-PRN [M 2]—583 (502 to 676)336 (286 to 395)—
SecondaryNumber of Subjects Reporting Any and Grade 3 Solicited Local Symptoms Post-meningococcal Vaccination

Solicited local symptoms assessed were pain, redness and swelling. Any was defined as occurrence of any local symptom irrespective of intensity grade. Grade 3 Pain was defined as crying when limb was moved/ spontaneously painful.

Time frame:
During the 4-day (Days 0-3) follow-up period after Nimenrix or Meningitec vaccination
Reported as:
Count of participants · Participants
Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms Post-meningococcal Vaccination
ParticipantsNimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa GroupMeningitec Group
Any Pain49303516
Grade 3 Pain3011
Any Redness70745636
Grade 3 Redness3882
Any Swelling42363623
Grade 3 Swelling2370
SecondaryNumber of Subjects Reporting Any and Grade 3 Solicited Local Symptoms Post-combined Diphtheria Vaccination

The analysis was based only on subjects receiving combined-diphtheria vaccination.

Time frame:
During the 4-day (Days 0-3) follow-up period after Infanrix-hexa vaccination
Reported as:
Count of participants · Participants
Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms Post-combined Diphtheria Vaccination
ParticipantsNimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa Group
Any Pain606564
Grade 3 Pain6510
Any Redness707799
Grade 3 Redness111427
Any Swelling485374
Grade 3 Swelling121422
SecondaryNumber of Subjects Reporting Any Solicited General Symptoms Following Each Dose

Solicited general symptoms assessed were drowsiness, fever, irritability and loss of appetite. Any was defined as occurrence of any general symptom irrespective of intensity grade and relationship. Subjects in the Nimenrix + Infanrix-hexa Group did not receive a second dose of vaccination.

Time frame:
During the 4-day (Days 0-3) post-vaccination dose 1 (D1) and second dose (D2)
Reported as:
Count of participants · Participants
Number of Subjects Reporting Any Solicited General Symptoms Following Each Dose
ParticipantsNimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa GroupMeningitec Group
Drowsiness, D185568029
Fever, D180417115
Irritability, D183637525
Loss of appetite, D151465115
Drowsiness, D2063560
Fever, D2060370
Irritability, D2075500
Loss of appetite, D2054380
SecondaryNumber of Subjects Reporting Any Rash

Any was defined as occurrence of at least one symptom experienced.

Time frame:
Day 0 - Month 7
Reported as:
Count of participants · Participants
Number of Subjects Reporting Any Rash
ParticipantsNimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa GroupMeningitec Group
Number of Subjects Reporting Any Rash13252212
SecondaryNumber of Subjects Reporting Any New Onset of Chronic Illnesses (NOCIs)

Any was defined as occurrence of at least one symptom experienced.

Time frame:
Day 0 - Month 7
Reported as:
Count of participants · Participants
Number of Subjects Reporting Any New Onset of Chronic Illnesses (NOCIs)
ParticipantsNimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa GroupMeningitec Group
Number of Subjects Reporting Any New Onset of Chronic Illnesses (NOCIs)1261
SecondaryNumber of Subjects Reporting Any Conditions Prompting Emergency Room Visits (ER)

Any was defined as occurrence of at least one symptom experienced.

Time frame:
Day 0 - Month 7
Reported as:
Count of participants · Participants
Number of Subjects Reporting Any Conditions Prompting Emergency Room Visits (ER)
ParticipantsNimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa GroupMeningitec Group
Number of Subjects Reporting Any Conditions Prompting Emergency Room Visits (ER)53146
SecondaryNumber of Subjects Reporting Any Unsolicited Adverse Events (AEs) After the First Dose

An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. "Any" was defined as an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.

Time frame:
Occurring within Day 0-30 following vaccination
Reported as:
Count of participants · Participants
Number of Subjects Reporting Any Unsolicited Adverse Events (AEs) After the First Dose
ParticipantsNimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa GroupMeningitec Group
Number of Subjects Reporting Any Unsolicited Adverse Events (AEs) After the First Dose71818342
SecondaryNumber of Subjects Reporting Any Unsolicited Adverse Events (AEs) After the Second Dose

An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. "Any" was defined as an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination. The analysis was based only on subjects receiving a second dose of vaccination.

Time frame:
Occurring within Day 0-30 following vaccination
Reported as:
Count of participants · Participants
Number of Subjects Reporting Any Unsolicited Adverse Events (AEs) After the Second Dose
ParticipantsNimenrix GroupInfanrix-Hexa Group
Number of Subjects Reporting Any Unsolicited Adverse Events (AEs) After the Second Dose8779
SecondaryNumber of Subjects Reporting Any Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/ incapacity.

Time frame:
From dose 1 (Month 0) up to study end (Month 7)
Reported as:
Count of participants · Participants
Number of Subjects Reporting Any Serious Adverse Events (SAEs)
ParticipantsNimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa GroupMeningitec Group
Number of Subjects Reporting Any Serious Adverse Events (SAEs)108116

Adverse events

Collected over SAEs were reported throughout the entire study period (Day 0 - Month 7). Solicited symptoms were reported during a 4-day period (Day 0-Day 3) after any vaccine dose, while unsolicited AEs were collected within 31 days (Days 0-30) after vaccination.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nimenrix + Infanrix-hexa Group0/222 (0%)10/222 (4.5%)166/222 (74.8%)
Nimenrix Group0/220 (0%)8/220 (3.6%)183/220 (83.2%)
Infanrix-Hexa Group1/224 (0.4%)11/224 (4.9%)185/224 (82.6%)
Meningitec Group0/127 (0%)6/127 (4.7%)75/127 (59.1%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventNimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa GroupMeningitec Group
BronchitisInfections and infestations1/2220/2200/2242/127
Febrile convulsionNervous system disorders2/2220/2201/2240/127
GastroenteritisInfections and infestations1/2221/2202/2240/127
Gastroenteritis rotavirusInfections and infestations1/2221/2202/2240/127
HypersensitivityImmune system disorders0/2220/2200/2241/127
BronchospasmRespiratory, thoracic and mediastinal disorders0/2220/2201/2241/127
AnaemiaBlood and lymphatic system disorders0/2221/2200/2241/127
Iron deficiencyMetabolism and nutrition disorders0/2220/2200/2241/127
Gastroenteritis norovirusInfections and infestations1/2220/2201/2241/127
Otitis mediaInfections and infestations0/2220/2201/2241/127
Most frequent other events
Showing 10 of 14
Most frequent other events
EventNimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa GroupMeningitec Group
ErythemaSkin and subcutaneous tissue disorders91/222102/220103/22436/127
IrritabilityPsychiatric disorders83/222100/22093/22425/127
SomnolenceNervous system disorders85/22289/22095/22429/127
PyrexiaGeneral disorders83/22290/22089/22417/127
SwellingGeneral disorders64/22266/22085/22423/127
Decreased appetiteMetabolism and nutrition disorders51/22278/22068/22415/127
PainGeneral disorders68/22275/22069/22416/127
Upper respiratory tract infectionInfections and infestations12/22227/22024/2248/127
GastroenteritisInfections and infestations6/22218/22018/2244/127
BronchitisInfections and infestations7/22216/22012/2246/127

Baseline characteristics

Age, Continuous
Age, Continuous(Months)Nimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa GroupMeningitec GroupTotal
Mean14.6 ± 3.0115 ± 3.3314.9 ± 3.1714.6 ± 2.9914.8 ± 3.14
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Nimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa GroupMeningitec GroupTotal
Female10910611961395
Male11311410566398
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Nimenrix + Infanrix-hexa GroupNimenrix GroupInfanrix-Hexa GroupMeningitec GroupTotal
White - Caucasian/ European heritage, n (%)204205212120741
African heritage / African American341210
American Indian or Alaskan native21014
Asian - Central/ South Asian heritage12104
Asian - East Asian heritage20002
Asian - South east Asian heritage20428
White - Arabic / North African heritage474217
Other41207
08

Study locations

89 sites
  • GSK Investigational Site
    Eferding, A-4070, Austria
  • GSK Investigational Site
    Neufeld/Leitha, A 2491, Austria
  • GSK Investigational Site
    Salzburg, A-5020, Austria
  • GSK Investigational Site
    Villach, A-9500, Austria
  • GSK Investigational Site
    Wels, A-4600, Austria
  • GSK Investigational Site
    Boennigheim, Baden-Wuerttemberg 74357, Germany
  • GSK Investigational Site
    Bretten, Baden-Wuerttemberg 75015, Germany
  • GSK Investigational Site
    Heilbronn, Baden-Wuerttemberg 74072, Germany
  • GSK Investigational Site
    Karlsruhe, Baden-Wuerttemberg 76189, Germany
  • GSK Investigational Site
    Mannheim, Baden-Wuerttemberg 68167, Germany
  • GSK Investigational Site
    Marbach, Baden-Wuerttemberg 71672, Germany
  • GSK Investigational Site
    Oberkirch, Baden-Wuerttemberg 77704, Germany
  • GSK Investigational Site
    Oberstenfeld, Baden-Wuerttemberg 71720, Germany
  • GSK Investigational Site
    Pforzheim, Baden-Wuerttemberg 75172, Germany
  • GSK Investigational Site
    Schwaebisch-Hall, Baden-Wuerttemberg 74523, Germany
  • GSK Investigational Site
    Stuttgart, Baden-Wuerttemberg 70469, Germany
  • GSK Investigational Site
    Tettnang, Baden-Wuerttemberg 88069, Germany
  • GSK Investigational Site
    Aschaffenburg, Bayern 63739, Germany
  • GSK Investigational Site
    Kaufbeuren, Bayern 87600, Germany
  • GSK Investigational Site
    Kaufering, Bayern 86916, Germany
  • GSK Investigational Site
    Kronach, Bayern 96317, Germany
  • GSK Investigational Site
    Muenchen, Bayern 81241, Germany
  • GSK Investigational Site
    Muenchen, Bayern 81675, Germany
  • GSK Investigational Site
    Muenchen, Bayern 81735, Germany
  • GSK Investigational Site
    Noerdlingen, Bayern 86720, Germany
  • GSK Investigational Site
    Olching, Bayern 82140, Germany
  • GSK Investigational Site
    Braunatal, Hessen 34225, Germany
  • GSK Investigational Site
    Eschwege, Hessen 37269, Germany
  • GSK Investigational Site
    Rodgau, Hessen 63110, Germany
  • GSK Investigational Site
    Wiesbaden, Hessen 65205, Germany
  • GSK Investigational Site
    Rostock, Mecklenburg-Vorpommern 18059, Germany
  • GSK Investigational Site
    Salzgitter, Niedersachsen 38226, Germany
  • GSK Investigational Site
    Wildeshausen, Niedersachsen 27793, Germany
  • GSK Investigational Site
    Bad Oeynhausen, Nordrhein-Westfalen 32549, Germany
  • GSK Investigational Site
    Balve, Nordrhein-Westfalen 58802, Germany
  • GSK Investigational Site
    Bochum, Nordrhein-Westfalen 44791, Germany
  • GSK Investigational Site
    Datteln, Nordrhein-Westfalen 45711, Germany
  • GSK Investigational Site
    Detmold, Nordrhein-Westfalen 32756, Germany
  • GSK Investigational Site
    Dortmund, Nordrhein-Westfalen 44329, Germany
  • GSK Investigational Site
    Dortmund, Nordrhein-Westfalen 44379, Germany
  • GSK Investigational Site
    Erkrath, Nordrhein-Westfalen 40699, Germany
  • GSK Investigational Site
    Espelkamp, Nordrhein-Westfalen 32339, Germany
  • GSK Investigational Site
    Goch, Nordrhein-Westfalen 47574, Germany
  • GSK Investigational Site
    Guetersloh, Nordrhein-Westfalen 33332, Germany
  • GSK Investigational Site
    Heiligenhaus, Nordrhein-Westfalen 42579, Germany
  • GSK Investigational Site
    Hille, Nordrhein-Westfalen 32479, Germany
  • GSK Investigational Site
    Kleve-Materborn, Nordrhein-Westfalen 47533, Germany
  • GSK Investigational Site
    Krefeld, Nordrhein-Westfalen 47798, Germany
  • GSK Investigational Site
    Loehne, Nordrhein-Westfalen 32584, Germany
  • GSK Investigational Site
    Minden, Nordrhein-Westfalen 32427, Germany
  • GSK Investigational Site
    Moenchengladbach, Nordrhein-Westfalen 41061, Germany
  • GSK Investigational Site
    Porta Westfalica, Nordrhein-Westfalen 32457, Germany
  • GSK Investigational Site
    Solingen, Nordrhein-Westfalen 42719, Germany
  • GSK Investigational Site
    Velbert, Nordrhein-Westfalen 42551, Germany
  • GSK Investigational Site
    Viersen, Nordrhein-Westfalen 41749, Germany
  • GSK Investigational Site
    Frankenthal, Rheinland-Pfalz 67227, Germany
  • GSK Investigational Site
    Gau-Odernheim, Rheinland-Pfalz 55239, Germany
  • GSK Investigational Site
    Mainz, Rheinland-Pfalz 55131, Germany
  • GSK Investigational Site
    Oppenheim, Rheinland-Pfalz 55276, Germany
  • GSK Investigational Site
    Speyer, Rheinland-Pfalz 67346, Germany
  • GSK Investigational Site
    Trier, Rheinland-Pfalz 54290, Germany
  • GSK Investigational Site
    Stollberg, Sachsen 09366, Germany
  • GSK Investigational Site
    Wurzen, Sachsen 04808, Germany
  • GSK Investigational Site
    Flensburg, Schleswig-Holstein 24937, Germany
  • GSK Investigational Site
    Flensburg, Schleswig-Holstein 24944, Germany
  • GSK Investigational Site
    Harrislee, Schleswig-Holstein 24955, Germany
  • GSK Investigational Site
    Husum, Schleswig-Holstein 25813, Germany
  • GSK Investigational Site
    Neumuenster, Schleswig-Holstein 24534, Germany
  • GSK Investigational Site
    Niebuell, Schleswig-Holstein 25899, Germany
  • GSK Investigational Site
    Lobenstein, Thueringen 07356, Germany
  • GSK Investigational Site
    Neuhaus am Rennweg, Thueringen 98724, Germany
  • GSK Investigational Site
    Weimar, Thueringen 99425, Germany
  • GSK Investigational Site
    Berlin, 10315, Germany
  • GSK Investigational Site
    Berlin, 10627, Germany
  • GSK Investigational Site
    Berlin, 12627, Germany
  • GSK Investigational Site
    Berlin, 12679, Germany
  • GSK Investigational Site
    Berlin, 13055, Germany
  • GSK Investigational Site
    Berlin, 13355, Germany
  • GSK Investigational Site
    Berlin, 13507, Germany
  • GSK Investigational Site
    Berlin, 14197, Germany
  • GSK Investigational Site
    Hamburg, 22089, Germany
  • GSK Investigational Site
    Hamburg, 22307, Germany
  • GSK Investigational Site
    Athens, 115 27, Greece
  • GSK Investigational Site
    Athens, 11527, Greece
  • GSK Investigational Site
    Didimoteicho, 68300, Greece
  • GSK Investigational Site
    Karditsa, 43100, Greece
  • GSK Investigational Site
    Komotini, 69 100, Greece
  • GSK Investigational Site
    Thessaloniki, 54636, Greece
  • GSK Investigational Site
    Veria, 591 00, Greece
09

References and documents

Publications

  • Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, Tichmann-Schumann I, Maurer H, Maurer L, Fischbach T, Zinke H, Pankow-Culot H, Papaevangelou V, Bianco V, Van der Wielen M, Miller JM. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. Vaccine. 2011 Jun 6;29(25):4264-73. doi: 10.1016/j.vaccine.2011.03.009. Epub 2011 Mar 21. PubMed 21420417 ↗
  • Maurer H et al. Co-administration of MENACWY-TT conjugate vaccine with DTPA-HBV-IPV/HIB vaccine does not impair immune response to DTPA-HBV-IPV/HIB, and has an acceptable safety profile. Abstract presented at the 28th Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID). Nice, France, 4-8 May 2010.

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007, a primary completion of May 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2019, 10 years 7 months after primary completion. A results delay was requested in Sep 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2007
First posted
Jul 27, 2007
Start
Aug 1, 2007
Primary completionActual
May 26, 2008
CompletionActual
Oct 27, 2008
Results delay requested
Sep 3, 2009
Results first posted
Jan 24, 2019
Last update
Jan 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00508261
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 27, 2007
Start date
Aug 1, 2007
Primary completion
May 26, 2008
Completion
Oct 27, 2008
Results posted
Jan 24, 2019
Last update
Jan 24, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine

Start the discussion